• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体和碳水化合物配体与 DC-SIGN 的结合可不同程度地调节受体运输。

Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.

机构信息

Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

出版信息

Eur J Immunol. 2012 Aug;42(8):1989-98. doi: 10.1002/eji.201142258.

DOI:10.1002/eji.201142258
PMID:22653683
Abstract

DCs are regarded as key APCs that initiate humoral and cellular immune responses. Consequently, targeted delivery of Ag toward DC-specific receptors enhances vaccine efficacy. DC-SIGN is a C-type lectin receptor that facilitates DC-specific delivery of Ag. This is accomplished by conjugating Ag to receptor-specific Ab or carbohydrate ligands that bind to its carbohydrate recognition domain. Here, we investigated the fate of DC-SIGN following receptor triggering with Ab. Both whole and single-chain Ab induced rapid internalization of about half of the surface receptor molecules. Biochemical studies showed that about half of the receptor molecules were still intracellular after 3 h, while minimal or no resurfacing of internalized or newly synthesized unbound DC-SIGN molecules was observed. Prolonged exposure of DCs to DC-SIGN Ab, but not carbohydrate ligands, resulted in reduced receptor expression levels, which lasted up to 2 days following removal of the Ab. In addition, exposure to DC-SIGN Ab reduced the ability of the receptor to internalize. Consequently, DC-SIGN showed a poor ability to accumulate targeting Abs within DCs. Vaccine efficacy may therefore be enhanced by strategies increasing the amount of Ag entering via a single receptor molecule, such as the use of targeting moieties allowing DC-SIGN recycling or Ab-coated vaccine carriers.

摘要

树突状细胞(DCs)被认为是启动体液和细胞免疫应答的关键抗原提呈细胞(APCs)。因此,针对 DC 特异性受体的抗原(Ag)靶向递呈可增强疫苗的功效。树突状细胞特异性 C 型凝集素受体(DC-SIGN)可促进 Ag 向 DC 特异性受体的递呈。这是通过将 Ag 与受体特异性抗体(Ab)或与碳水化合物识别域结合的碳水化合物配体偶联来实现的。在此,我们研究了 Ab 与受体结合后 DC-SIGN 的命运。完整抗体和单链抗体均诱导约一半表面受体分子的快速内化。生化研究表明,约一半的受体分子在 3 小时后仍在细胞内,而内化或新合成的未结合的 DC-SIGN 分子几乎没有或没有重新出现在细胞表面。DC 持续暴露于 DC-SIGN Ab 但不暴露于碳水化合物配体,会导致受体表达水平降低,在 Ab 去除后可持续长达 2 天。此外,暴露于 DC-SIGN Ab 会降低受体的内化能力。因此,DC-SIGN 积累 DC 内靶向 Ab 的能力较差。因此,通过增加通过单个受体分子进入的 Ag 量的策略(例如使用允许 DC-SIGN 再循环或 Ab 包被的疫苗载体的靶向部分),可以增强疫苗的功效。

相似文献

1
Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.抗体和碳水化合物配体与 DC-SIGN 的结合可不同程度地调节受体运输。
Eur J Immunol. 2012 Aug;42(8):1989-98. doi: 10.1002/eji.201142258.
2
Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.通过 DC-SIGN 将抗体和碳水化合物与靶向疫苗比较,以作用于人类树突状细胞。
Biomaterials. 2012 Jun;33(16):4229-39. doi: 10.1016/j.biomaterials.2012.02.036. Epub 2012 Mar 10.
3
The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.聚乙二醇(PEG)链长和靶向部分对抗体介导的纳米疫苗递送至人树突状细胞的影响。
Biomaterials. 2011 Oct;32(28):6791-803. doi: 10.1016/j.biomaterials.2011.04.082. Epub 2011 Jul 2.
4
Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.靶向 PLGA 纳米颗粒而非微米颗粒可通过 DC-SIGN 特异性地将抗原递呈给体外的人树突状细胞。
J Control Release. 2010 Jun 1;144(2):118-26. doi: 10.1016/j.jconrel.2010.02.013. Epub 2010 Feb 13.
5
Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.mRNA 展示筛选的抗体模拟配体靶向树突状细胞特异性 C 型凝集素用于树突状细胞导向的抗原递呈。
ACS Chem Biol. 2013 May 17;8(5):967-77. doi: 10.1021/cb300680c. Epub 2013 Mar 8.
6
Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils.DC-SIGN与Mac-1和CEACAM1的相互作用调节树突状细胞与中性粒细胞之间的接触。
FEBS Lett. 2005 Nov 7;579(27):6159-68. doi: 10.1016/j.febslet.2005.09.089. Epub 2005 Oct 13.
7
Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.基于聚糖的树突状细胞特异性细胞间黏附分子-3 结合非黏附分子靶向疫苗增强抗原交叉呈递。
Mol Immunol. 2013 Sep;55(2):143-5. doi: 10.1016/j.molimm.2012.10.031. Epub 2012 Nov 14.
8
The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.树突状细胞特异性C型凝集素DC-SIGN是曼氏血吸虫卵抗原的受体,可识别聚糖抗原Lewis x。
Glycobiology. 2003 Jun;13(6):471-8. doi: 10.1093/glycob/cwg052. Epub 2003 Feb 20.
9
Measles virus targets DC-SIGN to enhance dendritic cell infection.麻疹病毒靶向树突状细胞特异性细胞间黏附分子-3抓取非整合素(DC-SIGN)以增强树突状细胞感染。
J Virol. 2006 Apr;80(7):3477-86. doi: 10.1128/JVI.80.7.3477-3486.2006.
10
Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.将糖基化修饰的卵清蛋白靶向小鼠树突状细胞特异性细胞间黏附分子-3抓取非整合素(DC-SIGN)转基因树突状细胞可增强MHC I类和II类分子的呈递。
Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8.

引用本文的文献

1
Trial watch: dendritic cell vaccination for cancer immunotherapy.试验观察:用于癌症免疫治疗的树突状细胞疫苗接种
Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019.
2
Antigen structure affects cellular routing through DC-SIGN.抗原结构通过 DC-SIGN 影响细胞途径。
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):14862-14867. doi: 10.1073/pnas.1820165116. Epub 2019 Jul 3.
3
Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
Toll 样受体 4 触发促进了 DC-SIGN 靶向抗原的细胞溶质途径,用于 MHC Ⅰ类分子的呈递。
Front Immunol. 2018 Jun 14;9:1231. doi: 10.3389/fimmu.2018.01231. eCollection 2018.
4
Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.鼠源 DC-SIGN/CD209a 作为抗原递呈和适应性免疫的靶点。
Front Immunol. 2018 May 7;9:990. doi: 10.3389/fimmu.2018.00990. eCollection 2018.
5
Trial watch: Dendritic cell-based anticancer immunotherapy.试验观察:基于树突状细胞的抗癌免疫疗法。
Oncoimmunology. 2017 May 12;6(7):e1328341. doi: 10.1080/2162402X.2017.1328341. eCollection 2017.
6
Trial watch: Dendritic cell-based anticancer therapy.试验观察:基于树突状细胞的抗癌疗法。
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.
7
The Consequences of Multiple Simultaneous C-Type Lectin-Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN.多种 C 型凝集素-配体相互作用的后果:DCIR 改变了 DC-SIGN 的内体-溶酶体途径。
Front Immunol. 2015 Mar 10;6:87. doi: 10.3389/fimmu.2015.00087. eCollection 2015.
8
Targeting the C-type lectins-mediated host-pathogen interactions with dextran.用葡聚糖靶向C型凝集素介导的宿主-病原体相互作用
J Pharm Pharm Sci. 2014;17(3):371-92. doi: 10.18433/j3n590.
9
Dendritic cell-targeted vaccines.树突状细胞靶向疫苗。
Front Immunol. 2014 May 30;5:255. doi: 10.3389/fimmu.2014.00255. eCollection 2014.
10
Trial watch: Dendritic cell-based interventions for cancer therapy.试验观察:基于树突状细胞的癌症治疗干预措施
Oncoimmunology. 2013 Oct 1;2(10):e25771. doi: 10.4161/onci.25771. Epub 2013 Jul 29.